Cannabis Science Inc (OTCMKTS:CBIS) COO Robert James Kane sold 200,000 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $0.13, for a total transaction of $26,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Robert James Kane also recently made the following trade(s):
- On Friday, December 29th, Robert James Kane sold 200,000 shares of Cannabis Science stock. The shares were sold at an average price of $0.10, for a total transaction of $20,000.00.
- On Thursday, November 30th, Robert James Kane sold 198,820 shares of Cannabis Science stock. The shares were sold at an average price of $0.06, for a total transaction of $11,929.20.
Cannabis Science Inc (CBIS) traded down $0.01 during midday trading on Friday, reaching $0.08. 39,591,101 shares of the company’s stock traded hands, compared to its average volume of 37,420,000. Cannabis Science Inc has a 1-year low of $0.03 and a 1-year high of $0.14.
TRADEMARK VIOLATION NOTICE: This report was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2018/01/05/robert-james-kane-sells-200000-shares-of-cannabis-science-inc-cbis-stock.html.
About Cannabis Science
Cannabis Science, Inc is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Receive News & Ratings for Cannabis Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannabis Science and related companies with MarketBeat.com's FREE daily email newsletter.